| Alpelisib studied in …STUDIED_INderived81 of 81show fewer |
|---|
| → studied in | NCT05038735Phase 3 · active not recruiting Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 81 trials list this drug (23 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05646862Phase 3 · recruiting A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01872260Phase 1/Phase 2 · active not recruiting Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04208178Phase 3 · active not recruiting Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04524000Phase 2 · active not recruiting Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544189Phase 2 · active not recruiting Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer · 81 trials list this drug (23 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05948943Phase 2/Phase 3 · recruiting Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679269Phase 2 · not yet recruiting Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. · 81 trials list this drug (23 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05508906Phase 1 · active not recruiting Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04251533Phase 3 · terminated Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss · 81 trials list this drug (23 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04997902Phase 1/Phase 2 · completed Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) · 81 trials list this drug (23 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05090358Phase 2 · active not recruiting Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03439046Phase 3 · terminated Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05631795Phase 4 · completed Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216472Phase 2 · terminated Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations · 81 trials list this drug (23 active) | — | — | Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04188548Phase 1 · active not recruiting A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05563220Phase 1/Phase 2 · active not recruiting Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04729387Phase 3 · terminated Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected · 81 trials list this drug (23 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05392608Phase 2 · active not recruiting SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) · 81 trials list this drug (23 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06083038completed Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983159Phase 2 · recruiting A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations · 81 trials list this drug (23 active) | — | — | Lymphangioma,Venous Hemangioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05143229Phase 1 · active not recruiting Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04085653available Managed Access Programs for BYL719, Alpelisib · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05230810Phase 1/Phase 2 · active not recruiting Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05101564Phase 2 · completed Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05501886Phase 3 · active not recruiting Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03138070NA · completed A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05933395Phase 2 · recruiting Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03056755Phase 2 · completed Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762979Phase 2 · active not recruiting Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03284957Phase 1/Phase 2 · terminated Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05063786Phase 3 · active not recruiting Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05625087Phase 2 · active not recruiting Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04300790Phase 2 · completed Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02437318Phase 3 · completed Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01870505Phase 1 · completed BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03207529Phase 1 · completed Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899349Phase 2 · terminated Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03631953Phase 1 · unknown Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas · 81 trials list this drug (23 active) | — | — | Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04862143Phase 2 · terminated Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03601507Phase 2 · terminated Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer · 81 trials list this drug (23 active) | — | — | Oropharyngeal Squamous Cell Carcinoma,Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05967286Phase 2 · withdrawn Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial · 81 trials list this drug (23 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 81 trials list this drug (23 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 81 trials list this drug (23 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03941782no longer available Compassionate Use of BYL 719 Alpelisib · 81 trials list this drug (23 active) | — | — | Lymphangioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01300962Phase 1 · completed Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02273219Phase 1 · completed Trial of AEB071 in Combination With BYL719 in Patients With Melanoma · 81 trials list this drug (23 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04801966NA · terminated Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study · 81 trials list this drug (23 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05472220Phase 1 · withdrawn Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma · 81 trials list this drug (23 active) | — | — | Adult Solid Neoplasm,Malignant Solid Neoplasm,Human Papillomavirus-Related Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03386162Phase 2 · terminated SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02506556Phase 2 · completed Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02734615Phase 1 · terminated Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03292250Phase 2 · completed Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] · 81 trials list this drug (23 active) | — | — | Head and Neck Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02282371Phase 1 · completed Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04526470Phase 1/Phase 2 · unknown Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer · 81 trials list this drug (23 active) | — | — | Solid Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03706573no longer available Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02167854Phase 1 · completed Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01719380Phase 2 · completed Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer · 81 trials list this drug (23 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04852081unknown Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02537223Phase 1 · completed Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer · 81 trials list this drug (23 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02155088Phase 1 · completed BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer · 81 trials list this drug (23 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02550743Phase 1 · terminated BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study · 81 trials list this drug (23 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01822613Phase 1 · completed Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) · 81 trials list this drug (23 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02088684Phase 1 · completed Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02144038Phase 1 · completed Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma · 81 trials list this drug (23 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02276027Phase 2 · completed A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer · 81 trials list this drug (23 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01613950Phase 1 · completed PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01928459Phase 1 · completed Phase 1b Trial of BGJ398/BYL719 in Solid Tumors · 81 trials list this drug (23 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01387321Phase 1 · completed A Study of BYL719 in Adult Patients With Advanced Solid Malignancies · 81 trials list this drug (23 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02051751Phase 1 · completed A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer · 81 trials list this drug (23 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02077933Phase 1 · completed Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors · 81 trials list this drug (23 active) | — | — | Neoplasm,Breast Neoplasm,Kidney Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01219699Phase 1 · completed A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02058381Phase 1 · completed A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02620839Phase 1 · terminated Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies · 81 trials list this drug (23 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01923168Phase 2 · completed Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women · 81 trials list this drug (23 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01708161Phase 1/Phase 2 · terminated A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02145312Phase 2 · unknown An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy. · 81 trials list this drug (23 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02298595Phase 1/Phase 2 · withdrawn Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma · 81 trials list this drug (23 active) | — | — | Squamous Cell Carcinoma,Oropharyngeal Neoplasm,Malignant Oropharyngeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01449058Phase 1 · completed A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors · 81 trials list this drug (23 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |